US 12,269,824 B2
Wild type kit inhibitors
Jason D. Brubaker, Cambridge, MA (US); Yinghui Dai, Cambridge, MA (US); Thomas A. Dineen, Cambridge, MA (US); Guangyan Du, Cambridge, MA (US); Cheng Fang, Cambridge, MA (US); Andrew Marc Haidle, Somerville, MA (US); Joseph L. Kim, Cambridge, MA (US); Emanuele Perola, Cambridge, MA (US); Thiwanka Samarakoon, Cambridge, MA (US); and Douglas Wilson, Cambridge, MA (US)
Assigned to Blueprint Medicines Corporation, Cambridge, MA (US)
Filed by Blueprint Medicines Corporation, Cambridge, MA (US)
Filed on Mar. 13, 2024, as Appl. No. 18/603,567.
Application 18/603,567 is a continuation of application No. PCT/US2023/081773, filed on Nov. 30, 2023.
Claims priority of provisional application 63/445,787, filed on Feb. 15, 2023.
Claims priority of provisional application 63/428,804, filed on Nov. 30, 2022.
Prior Publication US 2024/0262826 A1, Aug. 8, 2024
Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); A61K 31/675 (2006.01); C07D 519/00 (2006.01); C07F 9/6524 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/437 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/5377 (2013.01); A61K 31/675 (2013.01); C07D 519/00 (2013.01); C07F 9/6524 (2013.01)] 34 Claims
 
1. A compound having the structure of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
Ring A is selected from tetrazole or triazole, wherein said tetrazole or triazole is optionally substituted with Ra;
wherein Ra is selected from hydrogen, C1-6 alkyl, C1-6haloalkyl, C0-5alkylphenyl, C0-5alkylC3-6cycloalkyl, C0-5alkylC6-10spirocycloalkyl, C0-5alkylC5-10bridgedbicycloalkyl, and C0-5alkyl(4-6 membered heterocycle), or C0-5alkyl(7-10 membered spiroheterocycle) or C0-5alkyl(5-10 membered bridgedbicycloheterocycle, each containing at least one N or O, wherein said alkyl, haloalkyl, phenyl, cycloalkyl, spirocycloalkyl, bridgedbicycloalkyl, heterocycle, spiroheterocycle, or bridgedbicycloheterocycle is optionally substituted with 1-5 Rb, wherein:
each Rb is independently selected from OH, CN, C1-6alkoxy, C1-6haloalkoxy, C3-5cycloalkoxy, SO2C1-4alkyl, SO2C1-4haloalkyl, C(O)OC1-4alkyl, SO2(C0-2alkyl)(4-6 membered heterocycle containing at least one O or N), SO2(C1-4alkyl)C1-4haloalkoxy, SO2(C1-4alkyl)C1-4alkoxy (C0-1alkoxy), SO2(C1-4alkyl)OH, SO2(C0-2alkyl)C3-6cycloalkyl, C1-3alkyl, C1-5haloalkyl, halogen, and C1-2alkylOH, further wherein said cycloalkyl is optionally substituted with C1-3alkyl;
each R1 is independently selected from halogen, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, C0-4alkylOH, C6-10spirocycloalkyl, C0-6alkylC1-6alkoxy, C0-4alkylC1-6haloalkoxy, NH2, NHC1-6alkyl, N(C1-6alkyl)2, NH-(4-6 membered heterocycle or 5-6 membered heteroaryl containing at least one O or N), and 4-6 membered heterocycle or 7-10 membered fused bicycloheterocycle or 7-10 membered spiroheterocycle, each containing at least one O or N, or 5-6 membered heteroaryl containing at least two N, wherein said alkyl, haloalkyl, alkoxy, cycloalkyl, spirocycloalkyl, heterocycle, or heteroaryl is optionally substituted with 1-3 Re;
each Re is independently selected from deuterium, deuterated C1-4alkyl, deuterated C1-4alkoxy, C1-4haloalkoxy, halogen, C0-3alkyl-S(O)2C1-3alkyl, C0-3alkyl-S(O)(NH) C1-3alkyl, (C1-4alkyl)P(O)(C1-3alkyl), C1-4alkyl, CN, CHF2, C3-6cycloalkyl, C1-4haloalkyl, C0-4alkylOH, C2-5alkyl(OH)2, C1-4alkyl(OH)(C1-C4alkoxy), C2-5alkyl(OH)(C1-5alkoxy)(C1-5alkoxy), C0-4alkylC1-4alkoxy, C1-3alkyoxyC1-3alkoxy, NH2, NH(C1-6alkyl), N(C1-6alkyl)2, and (C0-4alkyl)-(4-6 membered heterocycle containing at least one O or N), wherein said heterocycle is optionally substituted with 1-3 C0-3alkylOH, or C1-3alkyl;
each R9 is independently selected from C1-3alkyl, C1-3haloalkyl, halogen, CN, and C3-4cycloalkyl;
n is 1 or 2; and
p is 0, 1 or 2.